These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 20307537)

  • 1. Bone marrow stromal cell interaction reduces syndecan-1 expression and induces kinomic changes in myeloma cells.
    Fuhler GM; Baanstra M; Chesik D; Somasundaram R; Seckinger A; Hose D; Peppelenbosch MP; Bos NA
    Exp Cell Res; 2010 Jul; 316(11):1816-28. PubMed ID: 20307537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mesenchymal stromal cells revert multiple myeloma cells to less differentiated phenotype by the combined activities of adhesive interactions and interleukin-6.
    Dezorella N; Pevsner-Fischer M; Deutsch V; Kay S; Baron S; Stern R; Tavor S; Nagler A; Naparstek E; Zipori D; Katz BZ
    Exp Cell Res; 2009 Jul; 315(11):1904-13. PubMed ID: 19328780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions.
    Bayer-Garner IB; Sanderson RD; Dhodapkar MV; Owens RB; Wilson CS
    Mod Pathol; 2001 Oct; 14(10):1052-8. PubMed ID: 11598177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment.
    Tai YT; Li XF; Breitkreutz I; Song W; Neri P; Catley L; Podar K; Hideshima T; Chauhan D; Raje N; Schlossman R; Richardson P; Munshi NC; Anderson KC
    Cancer Res; 2006 Jul; 66(13):6675-82. PubMed ID: 16818641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Flow cytometric evaluation of bone marrow plasma cells using CD19, CD45, CD56, CD38, and CD138 and correlation with bone marrow infiltration ratio in multiple myeloma patients.
    Kara IO; Sahin B; Paydas S; Cetiner S
    Saudi Med J; 2004 Nov; 25(11):1587-92. PubMed ID: 15573184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The RANK/RANK ligand system is involved in interleukin-6 and interleukin-11 up-regulation by human myeloma cells in the bone marrow microenvironment.
    Giuliani N; Colla S; Morandi F; Rizzoli V
    Haematologica; 2004 Sep; 89(9):1118-23. PubMed ID: 15377473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-primed natural killer cells from patients with multiple myeloma lyse autologous, NK-resistant, bone marrow-derived malignant plasma cells.
    Katodritou E; Terpos E; North J; Kottaridis P; Verrou E; Gastari V; Chadjiaggelidou C; Sivakumaran S; Jide-Banwo S; Tsirogianni M; Kapetanos D; Zervas K; Lowdell MW
    Am J Hematol; 2011 Dec; 86(12):967-73. PubMed ID: 21919039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High heparanase activity in multiple myeloma is associated with elevated microvessel density.
    Kelly T; Miao HQ; Yang Y; Navarro E; Kussie P; Huang Y; MacLeod V; Casciano J; Joseph L; Zhan F; Zangari M; Barlogie B; Shaughnessy J; Sanderson RD
    Cancer Res; 2003 Dec; 63(24):8749-56. PubMed ID: 14695190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
    Voorhees PM; Chen Q; Kuhn DJ; Small GW; Hunsucker SA; Strader JS; Corringham RE; Zaki MH; Nemeth JA; Orlowski RZ
    Clin Cancer Res; 2007 Nov; 13(21):6469-78. PubMed ID: 17975159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of in vitro growth of multiple myeloma cells.
    Zlei M; Egert S; Wider D; Ihorst G; Wäsch R; Engelhardt M
    Exp Hematol; 2007 Oct; 35(10):1550-61. PubMed ID: 17889722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A subpopulation of malignant CD34+CD138+B7-H1+ plasma cells is present in multiple myeloma patients.
    Kuranda K; Berthon C; Dupont C; Wolowiec D; Leleu X; Polakowska R; Jouy N; Quesnel B
    Exp Hematol; 2010 Feb; 38(2):124-31. PubMed ID: 19948206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD138/syndecan-1: a useful immunohistochemical marker of normal and neoplastic plasma cells on routine trephine bone marrow biopsies.
    Chilosi M; Adami F; Lestani M; Montagna L; Cimarosto L; Semenzato G; Pizzolo G; Menestrina F
    Mod Pathol; 1999 Dec; 12(12):1101-6. PubMed ID: 10619261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. APRIL and TACI interact with syndecan-1 on the surface of multiple myeloma cells to form an essential survival loop.
    Moreaux J; Sprynski AC; Dillon SR; Mahtouk K; Jourdan M; Ythier A; Moine P; Robert N; Jourdan E; Rossi JF; Klein B
    Eur J Haematol; 2009 Aug; 83(2):119-29. PubMed ID: 19456850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A single-chain Fv diabody against human leukocyte antigen-A molecules specifically induces myeloma cell death in the bone marrow environment.
    Sekimoto E; Ozaki S; Ohshima T; Shibata H; Hashimoto T; Abe M; Kimura N; Hattori K; Kawai S; Kinoshita Y; Yamada-Okabe H; Tsuchiya M; Matsumoto T
    Cancer Res; 2007 Feb; 67(3):1184-92. PubMed ID: 17283154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pyridone 6, a pan-Janus-activated kinase inhibitor, induces growth inhibition of multiple myeloma cells.
    Pedranzini L; Dechow T; Berishaj M; Comenzo R; Zhou P; Azare J; Bornmann W; Bromberg J
    Cancer Res; 2006 Oct; 66(19):9714-21. PubMed ID: 17018630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrin alpha4beta1 involvement in stromal cell-derived factor-1alpha-promoted myeloma cell transendothelial migration and adhesion: role of cAMP and the actin cytoskeleton in adhesion.
    Parmo-Cabañas M; Bartolomé RA; Wright N; Hidalgo A; Drager AM; Teixidó J
    Exp Cell Res; 2004 Apr; 294(2):571-80. PubMed ID: 15023543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD138-negative myeloma cells regulate mechanical properties of bone marrow stromal cells through SDF-1/CXCR4/AKT signaling pathway.
    Wu D; Guo X; Su J; Chen R; Berenzon D; Guthold M; Bonin K; Zhao W; Zhou X
    Biochim Biophys Acta; 2015 Feb; 1853(2):338-47. PubMed ID: 25450979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD138 (syndecan-1), a plasma cell marker immunohistochemical profile in hematopoietic and nonhematopoietic neoplasms.
    O'Connell FP; Pinkus JL; Pinkus GS
    Am J Clin Pathol; 2004 Feb; 121(2):254-63. PubMed ID: 14983940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance.
    Yasui H; Hideshima T; Raje N; Roccaro AM; Shiraishi N; Kumar S; Hamasaki M; Ishitsuka K; Tai YT; Podar K; Catley L; Mitsiades CS; Richardson PG; Albert R; Brinkmann V; Chauhan D; Anderson KC
    Cancer Res; 2005 Aug; 65(16):7478-84. PubMed ID: 16103102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma.
    Gunn WG; Conley A; Deininger L; Olson SD; Prockop DJ; Gregory CA
    Stem Cells; 2006 Apr; 24(4):986-91. PubMed ID: 16293576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.